Jointown(SH:600998)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥35,006,769,007.21, representing a year-on-year increase of 0.13%[3]. - The net profit attributable to shareholders for Q3 2023 was ¥480,681,326.13, reflecting a year-on-year growth of 2.34%[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥432,348,844.82, up 5.70% compared to the same period last year[3]. - For the first nine months of 2023, the operating revenue increased by 11.09% year-on-year, driven by significant growth in various business segments[6]. - The company achieved a revenue of 114.36 billion RMB in the first three quarters of 2023, representing an increase of 11.09% compared to the same period last year[15]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 1.728 billion RMB, up 14.01% year-on-year[15]. - The total revenue for the first three quarters of 2023 reached ¥114.36 billion, an increase from ¥102.95 billion in the same period of 2022, representing a growth of approximately 11.5%[40]. - The total operating costs for the first three quarters of 2023 were ¥111.80 billion, compared to ¥100.79 billion in the same period of 2022, indicating an increase of about 10.0%[40]. Cash Flow and Assets - The cash flow from operating activities for the first nine months of 2023 saw a substantial increase of 154.30% year-on-year, indicating improved operational quality[6]. - The net cash flow from operating activities reached 799 million RMB, a significant increase of 154.30% compared to the same period last year[15]. - As of September 30, 2023, the company's cash and cash equivalents were approximately ¥14.32 billion, down from ¥17.18 billion at the end of 2022, reflecting a decrease of about 16.5%[38]. - The company's accounts receivable increased to approximately ¥36.26 billion, up from ¥27.58 billion year-over-year, indicating growth in sales and credit extension[38]. - The total assets as of the end of Q3 2023 were ¥92,938,128,963.92, a slight increase of 0.72% from the end of the previous year[4]. - The total liabilities amounted to ¥64.63 billion, an increase from ¥63.59 billion in the previous quarter, showing a rise of about 1.6%[40]. - The company's total assets reached ¥92.94 billion, compared to ¥92.27 billion in the previous quarter, marking an increase of approximately 0.7%[40]. Business Segments and Growth - The gross profit from the general agency brand promotion business increased by 41.49% year-on-year, contributing to overall revenue growth[6]. - The total brand promotion business revenue grew by 25.90% year-on-year, with gross profit increasing by 41.49%[15]. - The pharmaceutical new retail business revenue increased by 26.21% year-on-year, with gross profit rising by 20.20%[15]. - The digital logistics technology and supply chain solutions business revenue grew by 31.59% year-on-year, with gross profit surging by 50.11%[15]. - The medical health and technology services business revenue increased by 23.21% year-on-year, with gross profit up by 36.52%[15]. - The self-operated business revenue of the Yaojiu B2B e-commerce platform reached 8.493 billion CNY in the first three quarters, becoming a leading out-of-hospital digital trading service platform in China[17]. - The retail e-commerce service platform generated revenue of 4.532 billion CNY in the first three quarters, a significant year-on-year increase of 52.77%[18]. Investments and Financial Activities - The company's investment income decreased by 84.08% year-to-date due to reduced investment gains from equity method accounting[12]. - The company's cash flow from investing activities showed a net outflow of 137.75% year-to-date, primarily due to the redemption of financial products in the previous year[12]. - The company has submitted an application for public REITs, utilizing approximately 3.3 million square meters of pharmaceutical logistics assets as underlying assets[27]. - The first batch of assets for the public REITs includes parts of the Wuhan East Lake Pharmaceutical Logistics Center, with a total building area expected to exceed 170,000 square meters[27]. Corporate Social Responsibility and Recognition - The company donated over ¥2.8 million in disaster relief materials in response to severe flooding in multiple regions, demonstrating its corporate social responsibility[35]. - The company ranked 57th in the "Top 500 Private Enterprises" and 15th in the "Top 100 Private Service Enterprises" in 2023, reflecting its strong market position[36]. - The company was recognized as an "A" level listed company for information disclosure for four consecutive years, highlighting its commitment to transparency[37]. Research and Development - Research and development expenses for Q3 2023 were approximately ¥131.41 million, up from ¥119.71 million in Q3 2022, marking an increase of about 9.1%[42]. - The clinical trial application for the oral COVID-19 drug SHEN211 was accepted by the National Medical Products Administration, marking a key innovation in the company's product pipeline[31]. Operational Efficiency - The company achieved a peak daily order volume of 190,000 and a monthly peak of 1.91 million orders at its first BC integrated warehouse in Hangzhou, showcasing operational efficiency[32]. - The logistics project for Tianjin Ainu Aisi Pharmaceutical Co., Ltd. increased storage capacity by 5 times and improved picking efficiency by 3 times, demonstrating advancements in logistics technology[32].